Market revenue in 2023 | USD 29.1 million |
Market revenue in 2030 | USD 68.2 million |
Growth rate | 12.9% (CAGR from 2023 to 2030) |
Largest segment | Kallikrein inhibitor |
Fastest growing segment | Kallikrein inhibitor |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | C1-esterase inhibitor, Bradykinin B2 receptor antagonist, Kallikrein inhibitor, Others Treatment |
Key market players worldwide | BioCryst Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, CSL Ltd, Adverum Biotechnologies Inc, KalVista Pharmaceuticals Inc, Takeda Pharmaceutical Co Ltd, Pharming Group, Attune Pharmaceuticals |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hereditary angioedema therapeutics market will help companies and investors design strategic landscapes.
Kallikrein inhibitor was the largest segment with a revenue share of 44.67% in 2023. Horizon Databook has segmented the Denmark hereditary angioedema therapeutics market based on c1-esterase inhibitor, bradykinin b2 receptor antagonist, kallikrein inhibitor, others treatment covering the revenue growth of each sub-segment from 2018 to 2030.
The Denmark hereditary angioedema therapeutics market is driven by the increasing prevalence of HAE in the country, advancements in medical research & technology, regulatory frameworks governing pharmaceuticals, and the competitive landscape among pharmaceutical companies offering condition related medications.
Furthermore, the market's performance is influenced by the overall healthcare infrastructure, public awareness campaigns, R&D activities, and any emerging trends or innovations in therapeutics. Pharmaceutical companies operating in this space may engage in product development, clinical trials, marketing, and collaborations with healthcare professionals to address the evolving needs of patients in Denmark.
Horizon Databook provides a detailed overview of country-level data and insights on the Denmark hereditary angioedema therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into Denmark hereditary angioedema therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account